|
Incorporated drug or substance | Lipid | Advantageous | System | References |
|
3′-Azido-3′-deoxythymidine palmitate | Trilaurin | Stable after autoclaving, and can be lyophilized and rehydrated | SLN | [51] |
|
5-Fluorouracil | Dynasa 114 and Dynasan 118 | Prolonged release in simulated colonic medium | SLN | [52] |
|
Apomorphine | Glyceryl monostearate, polyethylene glycol monostearate | Enhanced the bioavailability in rats | SLN | [20] |
|
Ascorbyl palmitate | Imwitor 900 and Labrafil M1944 | Viscoelastic measurements is appropriate for topical/dermal application | NLC | [53] |
|
Baclofen | Stearic acid | Significantly higher drug concentrations in plasma | SLN | [54] |
|
Benzyl nicotinate | Dynasan 116 | Increased oxygenation in the skin | SLN | [55] |
|
Calcitonin | Trimyristin | Improvement of the efficiency of such carriers for oral delivery of proteins | SLN | [56] |
|
Camptothecin | Monostearin and Soybean Oil 788 | Stable and high performance delivery system | NLC | [57, 58] |
|
Clozapine | Trimyristin, tripalmitin, and tristearin | Improvement of bioavailability | SLN | [59] |
|
Cyclosporin A | glyceryl monostearate, and glyceryl palmitostearate | Controlled release | SLN | [60, 61] |
|
Dexamethasone | Compritol 888 ATO | Drug delivery topical use | SLN | [62] |
|
Diazepam | Compritol ATO 888 and Imwitor 900 K | Prolonged release | SLN | [63] |
|
Doxorubicin | Glyceryl caprate | Enhanced apoptotic death | SLN | [64] |
|
Gonadotropin release hormone | Monostearin | Prolonged release | SLN | [65] |
|
Hydrocortisone | Monoglyceride, chain length of the fatty acid moiety | SLN stable with release properties | SLN | [66] |
|
Ibuprofen | stearic acid, triluarin, tripalmitin | Stable formulation and negligible cell cytotoxicity | SLN | [67] |
|
Idarubicin | Emulsifying wax | Potential to deliver anticancer drugs | SLN | [68] |
|
Insulin | Stearic acid, octadecyl alcohol, cetyl palmitate, glyceryl monostearate, glyceryl palmitostearate, glyceryl tripalmitate, glyceryl behenate | Promising for oral delivery of proteins | SLN | [50] |
|
Ketoprofen | mixture of beeswax and carnauba wax | SLN with beeswax content exhibited faster drug release as compared carnauba wax | SLN | [69] |
|
Lopinavir | Compritol 888 ATO | Bioavailability enhanced | SLN | [70] |
|
Nimesulide | Glyceryl behenate, palmitostearate, glyceryl tristearate | Sustained drug release | SLN | [71] |
|
Penciclovir | Glyceryl monostearate | Provide a good skin targeting | SLN | [72] |
|
Progesterone | Monostearin, stearic acid and oleic acid | Potential drug delivery system for oral administration | NLC | [73, 74] |
|
Repaglinide | Glycerol monostearate and tristearin | Toxicity study indicated that the SLN were well tolerated | SLN | [22, 49] |
|
Salbutamol sulphate | Monostearin and PEG2000 | Formulation accelerate release of hydrophilic small molecule drugs | SLN | [75] |
|
Tetracycline | glyceryl monostearate and stearic acid | Sustained release | SLN | [76] |
|